相关实验视频

Updated: Jun 30, 2025

Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction

Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction

Published on: April 14, 2022

综合性多组体分析识别了基因支持的可用药物标和免疫细胞特异性,用于肌痛性骨髓灰质炎

Jiao Li^1,2,3, Fei Wang^1,3, Zhen Li¹

¹Department of Neurology, Xuanwu Hospital, National Center for Neurological Disorders, Capital Medical University, Beijing, 100053, China.

Journal of translational medicine

|March 24, 2024

概括

这项研究确定了T_H2细胞中的CTSH基因表达作为肌痛性硬化症 (MG) 的潜在因果因素. 这些发现突出了 MG 药物开发的新治疗目标,解决未满足的临床需求.

科学领域:

遗传学遗传学是一个
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

骨髓灰质炎 (MG) 是一种自身免疫性疾病,导致肌肉衰弱,目前的治疗方法往往不理想.
对于新型治疗药物来有效管理MG症状和副作用的需求至关重要.

研究的目的:

研究遗传因素 (eQTL和pQTL) 与MG易感性之间的因果关系.
探索对MG风险的遗传影响的细胞类型特异性.

主要方法:

利用门德尔的随机化 (MR) 和同地化分析来评估遗传关联.
使用免疫细胞特定的eQTL和pQTL来识别潜在的因果基因和蛋白质.
使用遗传局部化分析研究了细胞类型的特异性.

主要成果:

确定了四个与MG易感性相关的基因 (CDC42BPB,CD226,PRSS36,TNFSF12) 和三种蛋白质 (CTSH,PRSS8,CPN2).
六个位点显示了与MG风险的显著局部化.
发现了强有力的证据,将T_H2细胞中的CTSH表达与MG风险联系起来 (后期概率=0.854).

结论:

CTSH是进一步研究和潜在的药物开发在MG的有希望的候选人.
这项研究揭示了免疫细胞调节机制,有助于MG.
进一步的研究对于验证这些发现和评估治疗潜力至关重要.

关键词:

可操作的可用药物基因组细胞类型的特异性遗传局部化遗传局部化门德尔的随机化骨髓灰质炎 (Myasthenia gravis) 是一个严重的疾病.

更多相关视频

Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts

Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts

Published on: September 20, 2024

Antigenic Liposomes for Generation of Disease-specific Antibodies

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

相关概念视频

Myasthenia Gravis: Diagnostic Tests

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...